Bookmark and Share
BioAssay: AID 429

HTS for Tumor Hsp90 Inhibitors

Hsp90 is a chaperon with important roles in maintaining transformation and in elevating the survival and growth potential of cancer cells. Recent evidence suggests additional applications of Hsp90 inhibitors in neurodegenerative diseases, nerve injuries, inflammation and infection. Several natural products that inactivate Hsp90 function have anti-tumor effects in in vitro and in vivo models more ..
_
   
 Tested Compounds
 Tested Compounds
All(63695)
 
 
Active(220)
 
 
Inactive(63477)
 
 
 Tested Substances
 Tested Substances
All(63918)
 
 
Active(223)
 
 
Inactive(63695)
 
 
 Related BioAssays
 Related BioAssays
AID: 429
Data Source: Emory University Molecular Libraries Screening Center
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Screening Center Network
BioAssay Version:
Deposit Date: 2006-06-22
Modify Date: 2007-10-18

Data Table ( Complete ):           View Active Data    View All Data
Targets
BioActive Compounds: 220
Related Experiments
AIDNameTypeComment
712Tumor Hsp90 Inhibitors Dose Response ConfirmationConfirmatorydepositor-specified cross reference
754Cell-based secondary assay for identifying Hsp90 inhibitors that degrade Hsp90 client protein Her2Confirmatorydepositor-specified cross reference
Description:
Emory Chemistry-Biology Discovery Center Assay Overview:

Hsp90 is a chaperon with important roles in maintaining transformation and in elevating the survival and growth potential of cancer cells. Recent evidence suggests additional applications of Hsp90 inhibitors in neurodegenerative diseases, nerve injuries, inflammation and infection. Several natural products that inactivate Hsp90 function have anti-tumor effects in in vitro and in vivo models of cancer. However, due to the role of Hsp90 in normal cellular homeostasis, it remained unclear whether Hsp90 inhibitors will be sufficiently specific for use as therapeutic agents. Early clinical results with 17AAG, the first Hsp90 inhibitor to enter clinical trials, confirm that Hsp90 is a promising target for novel cancer therapeutics and pave the road for the introduction of Hsp90 inhibitors in the clinic. The potential of Hsp90 inhibitors as therapeutics in other diseases has been less explored. Currently there is thus, increasing interest in developing novel inhibitors of this protein.

We have developed and optimized a fluorescence polarization based HTS assay for the identification of Hsp90 inhibitors by using tumor cell lysate Hsp90. Geldanamycin (GM) is a natural product that inhibits Hsp90 by binding to its ATP pocket. The FP assay for the Hsp90 in cell lysate is based on the competitive binding of fluorescently (Cy3B) labeled geldanamycin (cy3B-GM) to average Hsp90 population found in cancer cell lysate (Y. Du, K. Moulick, J. Aguirre, H. Fu, G. Chiosis. Development of a high-throughput screening fluorescence polarization assay for thetumor Hsp90. Manuscript in preparation).
Protocol
Reagents:
1. Binding buffer: 20 mM HEPES, 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.01% NP40. Before use, 0.1 mg/ml of BGG, 2mM of DTT are added.
2. NCI-N417 cell lysate preparation: The human cancer cell line NCI-N417 is obtained from the American Type Culture Collection (Manassas, VA). Cells are cultured routinely in RPMI supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 1.5g/L sodium bicarbonate, 4.5g/L glucose, 10% fetal bovine serum, 1% L-glutamine, 1% penicillin and streptomycin. Cells are frozen to rapture the membrane and then dissolved in binding buffer (20mM HEPES, 50mM KCl,5mM MgCl2, 20mM Na2MoO4, 0.01% NP40, freshly add 0.1 mg/ml BGG, 2 mM DTT) to form the lysate. Lysate is stored at -20 degrees C before use.
3. GM-cy3B stock in DMSO.
4. PU-H71 as positive control: 10 mM stock in DMSO
Procedures:
1.Make assay reaction buffer for HTS (1ug/well N417 cell lysate and 5 nM of GM-Cy3B in binding buffer).
2. Dispense 49.5uL of assay reaction buffer to 384-well black assay plate.
3. Add 0.75uL of 2mM compounds in DMSO (1.5% DMSO final) and incubate plates at room temperature for overnight (15 hr). Final compound concentration is 30uM.
4. Fluorescence polarization in mP is measured at room temperature with an Analyst HT reader. An excitation filter at 545nm and an emission filter at 610 to 675nm are used with a dichroic mirror of 565nm.
Data analysis:
Assay data are analyzed using CambridgeSoft. Templates have been written that will automatically calculate % of inhibition. Percentage of inhibition is calculated by the equation based on per plate:
% of Inhibition = 100 - ((mPc - mPf)/(mPb - mPf)) * 100
Where mPc is the recorded mP from compound wells; mPf is average recorded mP from cy3B-GM only wells; mPb is average recorded mP from wells containing cy3B-GM and NCI-N417 lysate.
An activity cutoff was set as a percent inhibition greater than 50%.
Comment
Possible interference in this assay, but are not limited to, compounds with auto-fluorescence, compounds quenching fluorescence, or precipitate.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1FP ValueFluorescence polarization (FP) value in millipolarization (mP) units was measured with an Analyst HT readerIntegermP
2% Inhibition% of inhibition is calculated by the equation based on per plate:
% of Inhibition = 100 - ((mPc - mPf)/(mPb - mPf)) * 100
Where mPc is the recorded mP from compound wells; mPf is average recorded mP from cy3B-GM only wells; mPb is average recorded mP from wells containing cy3B-GM and NCI-N417 lysate.
Float%

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: